home / stock / ulti / ulti quote
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $331.36 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $331.36 | $N/A | $N/A | 0 | 05-07-2019 |
$ | $N/A | $331.36 | $N/A | $N/A | 0 | 05-06-2019 |
$ | $N/A | $331.36 | $N/A | $N/A | 0 | 05-03-2019 |
$ | $331.31 | $331.36 | $331.42 | $331.25 | 1,531,074 | 05-02-2019 |
$ | $330.90 | $331.27 | $331.34 | $330.75 | 639,535 | 05-01-2019 |
$ | $330.79 | $330.65 | $331.00 | $330.65 | 333,640 | 04-30-2019 |
$ | $330.25 | $330.70 | $330.96 | $330.25 | 382,982 | 04-29-2019 |
$ | $330.84 | $330.19 | $330.89 | $329.69 | 636,714 | 04-26-2019 |
$ | $331.00 | $330.73 | $331.10 | $330.63 | 515,448 | 04-25-2019 |
$ | $330.95 | $330.85 | $331.13 | $330.30 | 1,012,727 | 04-24-2019 |
$ | $330.78 | $331.02 | $331.15 | $330.71 | 408,256 | 04-23-2019 |
$ | $330.30 | $330.84 | $330.85 | $330.30 | 446,497 | 04-22-2019 |
$ | $330.38 | $330.41 | $330.50 | $330.10 | 401,506 | 04-19-2019 |
$ | $330.38 | $330.41 | $330.50 | $330.10 | 401,506 | 04-18-2019 |
$ | $330.31 | $330.40 | $330.45 | $330.12 | 384,325 | 04-17-2019 |
$ | $330.40 | $330.40 | $330.47 | $330.05 | 467,415 | 04-16-2019 |
$ | $330.30 | $330.35 | $330.55 | $330.25 | 308,703 | 04-15-2019 |
$ | $330.33 | $330.30 | $330.48 | $330.14 | 463,476 | 04-12-2019 |
$ | $330.35 | $330.33 | $330.41 | $330.17 | 393,511 | 04-11-2019 |
$ | $330.30 | $330.21 | $330.46 | $330.21 | 280,551 | 04-10-2019 |
News, Short Squeeze, Breakout and More Instantly...
The Ultimate Software Group Inc. Company Name:
ULTI Stock Symbol:
NASDAQ Market:
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 months Study provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 202 2 : ...
Oslo, 21. March 2022 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that it will host a key opinion leader (KOL) webinar on the unmet need and treatment landscape of melanoma on Monday, March 28, 2...
Oslo, 1 7 February 202 2 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its fourth quarter 2021 results today. The presentation by the company's management team can be followed as a liv...